Health tech contributes $1.3b, 'major growth potential'
A review of the health technology and medical devices sectors shows the industry has the fastest growth in IT spending.
AdvertisementAdvertise with NZME.
Latest FromBiotechnology
LanzaTech makes global disruption list
New Zealand-founded LanzaTech has been ranked thirteenth on CNBC's Disruptors list for 2016.
Kiwi biotech firm seeking funding for Zika test
Kiwi biotech firm Ubiquitome is seeking clearance from the FDA to secure a Zika diagnostic test.
Orion Health partners in govt-backed research
Orion Health, Waitemata DHB and University of Auckland are part of a $37 million healthcare research collaboration.
The big sleep
Two of the 0.2mm-long creatures, and a separate egg, were able to be revived after being frozen for more than 30 years.
China to make test tube beef
China is taking steps to genetically engineer its own food supply rather than growing it the boring old traditional way.
San Francisco startup spins lab-grown silk
A San Francisco startup has developed a synthetic alternative to spider silk by engineering identical proteins.
Christopher Niesche: Biotech stocks a lottery
Last Thursday we saw a tale of two biotech companies. If you need evidence investing in medical research stocks is a lottery, this is the story for you, writes Christopher Niesche.
Much to learn about the fabric of life
A process that could turn harmful gases into useful products like car tyres shows why scientists need to keep challenging our understanding of what are the proteins vital to all life on Earth.
Eric Watson: Gene dilemma as food gets low
As a species we face a conundrum: we have become so good at survival that we face sustainability issues caused by our population and consumption, Eric Watson writes.
Katie Benner: Are we feeling nervous yet about a biotech bubble?
Nasdaq's biotech companies have returned 500 per cent gains to shareholders since 2011, versus 97 per cent for the Nasdaq's Internet stocks.
Synthetic biology offers hope with incurables
A new way of treating incurable illnesses such as cancer and Ebola could be possible after a scientific breakthrough that also sheds light on the origin of life.
Cost to develop a new drug more than doubles
It costs drugmakers US$2.56 billion to bring a new medicine to market - more than double the price of 11 years ago.
LanzaTech raises a further $60m
New Zealand-founded bio-fuels innovator LanzaTech has attracted US$60 million in its latest capital-raising round,
Out of the Alaskan fridge and into NZ's hi tech cauldron
Wellington's notoriously volatile weather is nothing compared with the climate Mary Quin faced in her previous home city.
Scientists begin to unlock Parkinson's mystery
The brains of patients with Parkinson's disease who had deep brain stimulation treatment produced new stem cells, according to new research.
First fully artificial heart in service
The lines of thousands of love poems and songs may have to be rewritten, according to Professor Alain Carpentier.
Google search ... and destroy
Computer giant's motto is 'Don't be evil', but some worry that tech purchase brings allure of defence contracts.
Kiwi biotech named in world's hottest
Auckland bio-fuels pioneer Lanzatech has been named the second "hottest" bio-technology company in the world and 4th hottest for bio-chemicals.
Parkinson's treatment trial starts
Human trials of a locally developed Parkinson's disease treatment have begun in New Zealand after the first round yielded promising results.
Green economy could pay for NZ
Mandatory emissions standards for new vehicles and an electrical "smart grid" are among a raft of ways New Zealand could tap into a global green economy.
Genomics could affect court decisions
Genome sequencing is “revolutionising” medicine, but could also impact on how society deals with criminals with a genetic predisposition towards violence.
Taiwan venture uses local technology
Technology developed by New Zealand's LanzaTech will lie at the heart of a new Taiwanese joint venture.
Should NZ grow genetically modified crops?
What are the benefits, if any? And is it inevitable? Two views from opposite sides of the argument from Agram chief executive Graeme Peters and university researcher Professor Jack Heinemann.
The singular vision of Peter Thiel
Why is this internet billionaire so keen on New Zealand? And why are we handing him taxpayers' money to invest? Chris Barton reports.
China Business 2012: Clearing the path for cleantech
Securing even a small slice of China's cleantech future will be a boon for Kiwi companies writes Ellen Read